Mednet Logo
HomeRadiation OncologyQuestion

Do you recommend chemoradiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?

1
4 Answers
Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

Tough question, with lots of evolution in this area in the past few years.

The data would suggest that for borderline resectable pancreatic cancer, there is a benefit in terms of OS from preoperative treatment. For unresectable disease, the small chance of conversion into resectability is worth the ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · National Comprehensive Cancer Network

The use of chemoradiation in resectable pancreatic cancer should not be considered the routine standard of care, but can be used strategically in borderline resectable tumors and tumors in which additional "space" is needed. While neoadjuvant therapy in pancreatic cancer is becoming more routine and...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Regional Cancer Care Associates, LLC

PREOPANC trial did not prove benefits, as per the recent final report. I think it may be useful in special borderline resectable situations...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Siri Onclogy and hematology Infusion Service

Local radiotherapy has never added to survival in localized pancreatic cancer and is not without toxicities. Why, with a more effective regimen, would it be expected to add now?

Register or Sign In to see full answer

Do you recommend chemoradiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer? | Mednet